{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:37:37Z","timestamp":1771886257184,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.farma.2022.12.016","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T23:40:21Z","timestamp":1682120421000},"page":"T39-T49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["[Translated article] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases"],"prefix":"10.1016","volume":"47","author":[{"given":"Olatz","family":"Ibarra Barrueta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Garc\u00eda Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piedad","family":"L\u00f3pez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Ram\u00edrez Herr\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Merino Boh\u00f3rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantza","family":"Ais Larisgoitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2022.12.016_bb0005","first-page":"e1","article-title":"La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en Espa\u00f1a","volume":"93","author":"Puig","year":"2019","journal-title":"Rev Esp Salud P\u00fablica"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.medcli.2016.11.008","article-title":"Pregnancy and autoimmune diseases","volume":"148","author":"Alijotas-Reig","year":"2017","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000018063","article-title":"Percutaneous absorption of salicylic acid in man after topical administration of three different formulations","volume":"198","author":"Schwarb","year":"1999","journal-title":"Dermatology."},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/1744666X.2015.1037742","article-title":"Psoriasis during pregnancy: characteristics and important management recommendations","volume":"11","author":"Hoffman","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2011.07.039","article-title":"Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Bae","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijwd.2019.05.002","article-title":"New changes in pregnancy and lactation labelling: Review of dermatologic drugs","volume":"5","author":"Koh","year":"2019","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0040","article-title":"Safety of dermatologic medications in pregnancy and lactation Part II","volume":"70","author":"Butler","year":"2014","journal-title":"Lactation J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40257-015-0137-5","article-title":"Treating psoriasis during pregnancy: safety and efficacy of treatments","volume":"16","author":"Bangsgaard","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MJT.0b013e31818a975c","article-title":"Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption","volume":"16","author":"Pariser","year":"2009","journal-title":"Am J Ther"},{"key":"10.1016\/j.farma.2022.12.016_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.sjpain.2017.09.007","article-title":"Is acetaminophen safe in pregnancy?","volume":"17","author":"Toda","year":"2017","journal-title":"Scand J Pain"},{"issue":"9","key":"10.1016\/j.farma.2022.12.016_bb0060","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3 Suppl","key":"10.1016\/j.farma.2022.12.016_bb0065","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.semarthrit.2019.09.010","article-title":"Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis","volume":"49","author":"Smeele","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0070","first-page":"62","article-title":"Riesgo de drogas antirreum\u00e1ticas frecuentemente usadas durante el embarazo","volume":"23","author":"Sapag Dur\u00e1n","year":"2012","journal-title":"Rev Arg Reumatol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2018.01.006","article-title":"Paternal exposure to antirheumatic drugs-What physicians should know: Review of the literature","volume":"48","author":"Micu","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00228-017-2385-1","article-title":"Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study","volume":"74","author":"Dathe","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0085","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/j.pain.0000000000001163","article-title":"Risk of preterm birth following late pregnancy exposure to NSAIDs or COX-2 inhibitors","volume":"159","author":"B\u00e9rard","year":"2018","journal-title":"Pain."},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2125.2005.02520.x","article-title":"Quantification of infant exposure to celecoxib through breast milk","volume":"61","author":"Gardiner","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reprod Toxicol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/j.1536-4801.1986.tb09071.x","article-title":"Bloody diarrhea: a possible complication of sulfasalazine transferred through human breast milk","volume":"5","author":"Branski","year":"1986","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","article-title":"Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence","volume":"48","author":"Mouyis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.farma.2022.12.016_bb0110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/tera.10043","article-title":"Teratogen update: azathioprine and 6-mercaptopurine","volume":"65","author":"Polifka","year":"2002","journal-title":"Teratology"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2022.12.016_bb0120","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]","volume":"142","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology."},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2016.10.013","article-title":"Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease","volume":"152","author":"Mahadevan","year":"2017","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/01443615.2012.716106","article-title":"The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy","volume":"33","author":"Hutson","year":"2013","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.gtc.2016.02.006","article-title":"Pregnancy and the patient with inflammatory bowel disease fertility, treatment, delivery, and complications","volume":"45","author":"McConnell","year":"2016","journal-title":"Gastroenterol Clin N Am"},{"issue":"27","key":"10.1016\/j.farma.2022.12.016_bb0150","first-page":"8790","article-title":"Treatment of Crohn's disease in pregnant women: Drug and multidisciplinary approaches","volume":"20","author":"Cury","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.farma.2022.12.016_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1365-2036.2008.03843.x","article-title":"Azathioprine treatment during lactation","volume":"28","author":"Christensen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2036.2004.01889.x","article-title":"The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception","volume":"19","author":"Norgard","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.22948","article-title":"Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease","volume":"19","author":"Akbari","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","article-title":"Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies","volume":"62","author":"Park-Wyllie","year":"2000","journal-title":"Teratology."},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22516","article-title":"Proceedings from the American College of rheumatology reproductive health summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases","volume":"67","author":"Kavanaugh.","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0180","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2018.09.031","article-title":"Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review","volume":"80","author":"Zakhem","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.07.002","article-title":"Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic","volume":"205","author":"Nurmohamed","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0190","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/rheumatology\/ket390","article-title":"No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study","volume":"53","author":"Weber-Schoendorfer","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0195","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","article-title":"Network of French Pharmacovigilance Centers. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study","volume":"66","author":"Weber-Schoendorfer","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/0891693031000067296","article-title":"Immunosuppressive Drug Use in Pregnancy","volume":"36","author":"Petri","year":"2003","journal-title":"Autoimmunity."},{"key":"10.1016\/j.farma.2022.12.016_bb0205","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","article-title":"Immunosuppressive drugs and fertility","volume":"10","author":"Leroy","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-5347(17)38318-0","article-title":"Male fertility in cyclosporine-treated renal transplant patients","volume":"145","author":"Haberman","year":"1991","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/and.12477","article-title":"Calcineurin inhibitors and male fertility after renal transplantation - a review","volume":"48","author":"Georgiou","year":"2016","journal-title":"Andrologia."},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1439-0272.2010.01052.x","article-title":"Characteristics of male fertility after renal transplantation","volume":"43","author":"Xu","year":"2011","journal-title":"Andrologia."},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Up date on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J Pediatr Genet"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0230","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajmg.a.35223","article-title":"Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services","volume":"158A","author":"Hoeltzenbein","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0235","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.farma.2022.12.016_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000001747","article-title":"Exposure to mycophenolate and fatherhood","volume":"101","author":"Midtvedt","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.jp.7211208","article-title":"Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation","volume":"25","author":"Motta","year":"2005","journal-title":"J Perinatol"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus."},{"issue":"12","key":"10.1016\/j.farma.2022.12.016_bb0255","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.3899\/jrheum.110686","article-title":"Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature","volume":"38","author":"Osadchy","year":"2011","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.farma.2022.12.016_bb0260","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.34419","article-title":"Pregnancy outcome in women exposed to leflunomide before or during pregnancy","volume":"64","author":"Cassina","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2022.12.016_bb0265","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.clineuro.2013.09.030","article-title":"Teriflunomide for the treatment of multiple sclerosis","volume":"115","author":"Warnke","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0270","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0275","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R","article-title":"Teratogen update: reproductive risks of Leflunomide (Arava); a pyrimidines synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child","volume":"63","author":"Brent","year":"2001","journal-title":"Teratology."},{"issue":"10","key":"10.1016\/j.farma.2022.12.016_bb0280","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-019-01141-w","article-title":"A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy","volume":"79","author":"Picardo","year":"2019","journal-title":"Drugs."},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/dth.12069","article-title":"Dermatological medication effects on male fertility","volume":"26","author":"Millsop","year":"2013","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.farma.2022.12.016_bb0290","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety database for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.farma.2022.12.016_bb0295","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17512433.2018.1525293","article-title":"The use of biologics and small molecules in pregnant patients with rheumatic diseases","volume":"11","author":"Gerosa","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0300","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"10.1016\/j.farma.2022.12.016_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223603","article-title":"Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study","volume":"14","author":"Chambers","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0310","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0315","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjd.15802","article-title":"Exposure to biological therapies during conception and pregnancy: a systematic review","volume":"178","author":"Pottinger","year":"2018","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.farma.2022.12.016_bb0320","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/jdv.14364","article-title":"Influence of TNF-alpha inhibitors and fumaric acid esters on male fertility in psoriasis patients","volume":"31","author":"Heppt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0325","first-page":"1014","article-title":"Tumor necrosis factor-alpha inhibition and VATER association: A causal relationship","volume":"33","author":"Carter","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0330","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: pregnancy and pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jri.2010.01.007","article-title":"Anti-TNF alpha therapy in immune-mediated subfertility: State of the art","volume":"85","author":"Clark","year":"2010","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.farma.2022.12.016_bb0340","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","article-title":"Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review","volume":"11","author":"Nielsen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.farma.2022.12.016_bb0345","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12456","article-title":"Safety issues of biologics in pregnant patients with rheumatic diseases","volume":"1317","author":"Ostensen","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2022.12.016_bb0350","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0016-5085(15)30482-0","article-title":"Detection of biologic agents in breast milk and implication for infection, growth and development in infants born to women with inflammatory bowel disease: results from the PIANO registry [abstract]","volume":"148","author":"Matro","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0355","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3899\/jrheum.080554","article-title":"Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab","volume":"36","author":"Paschou","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0360","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10875-007-9071-5","article-title":"Effects of tumor necrosis factor-alpha on human sperm motility and apoptosis","volume":"27","author":"Perdichizzi","year":"2007","journal-title":"J Clin Immunol"},{"issue":"10","key":"10.1016\/j.farma.2022.12.016_bb0365","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/ard.2009.127423","article-title":"Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis","volume":"69","author":"Villiger","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.farma.2022.12.016_bb0370","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: Updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.farma.2022.12.016_bb0375","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jth.13366","article-title":"Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH","volume":"14","author":"Cohen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0380","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/17512433.2017.1305268","article-title":"The use of biologics in pregnant patients with rheumatic disease","volume":"10","author":"Ostensen","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0385","first-page":"1021","article-title":"Successful outcome of two pregnancies in patients with adult-onset still's disease treated with IL-1 receptor antagonist (anakinra)","volume":"29","author":"Fischer-Betz","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.farma.2022.12.016_bb0390","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/art.38811","article-title":"Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS)","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.farma.2022.12.016_bb0395","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2022.12.016_bb0400","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1297-319X(12)70011-8","article-title":"Abatacept therapy and safety management","volume":"79","author":"Pham","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0405","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2015.06.016","article-title":"Pregnancy outcomes following exposure to abatacept during pregnancy","volume":"45","author":"Kumar","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.farma.2022.12.016_bb0410","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0415","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/bdrb.21019","article-title":"The effects of interleukin-6 signal blockade on fertility, embryo-fetal development, and immunization in vivo","volume":"95","author":"Sakurai","year":"2012","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0420","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.farma.2022.12.016_bb0425","doi-asserted-by":"crossref","first-page":"ID271363","DOI":"10.1155\/2008\/271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"10.1016\/j.farma.2022.12.016_bb0430","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.farma.2022.12.016_bb0435","doi-asserted-by":"crossref","first-page":"AB178","DOI":"10.1016\/j.jaad.2014.01.740","article-title":"Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program [abstract]","volume":"70","author":"Schaufelberg","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.farma.2022.12.016_bb0440","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"45","author":"Mahadevan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.farma.2022.12.016_bb0445","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/17474124.2018.1496820","article-title":"Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system","volume":"12","author":"Wieringa","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0450","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0455","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.08.067","article-title":"Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease","volume":"154","author":"Julsgaard","year":"2018","journal-title":"Gastroenterology."},{"issue":"7","key":"10.1016\/j.farma.2022.12.016_bb0460","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"5","author":"Mahadevan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.farma.2022.12.016_bb0465","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2 Pt A","key":"10.1016\/j.farma.2022.12.016_bb0470","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"Irani","year":"2015","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.farma.2022.12.016_bb0475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bjd.18897","article-title":"Outcomes of Pregnancies from the tildrakizumab phase I-III clinical development program","volume":"183","author":"Haycraft","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.farma.2022.12.016_bb0480","author":"Odufalu","year":"2021","journal-title":"Gut Epub"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0485","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ibd\/izaa122","article-title":"The risk of adverse neonatal outcomes with maternal inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Leung","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.farma.2022.12.016_bb0490","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.farma.2022.12.016_bb0495","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheum"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634322000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634322000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:37Z","timestamp":1761106657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634322000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1130634322000253"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2022.12.016","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2022.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2022.12.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}